Global Malignant Peripheral Nerve Sheath Tumor Treatment Market, by Treatment Type (Surgery, Radiation Therapy, Chemotherapy), By End Users (Hospitals, Clinics, ASCs), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a healthy CAGR for the period between 2020 and 2028.
As per the report, the mounting incidence of soft tissue sarcoma and improving diagnosis rates are the major factors attributed to the growth of the malignant peripheral nerve sheath tumor treatment market. Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas that originate from peripheral nerves or from cells associated with the nerve sheath. Malignant peripheral nerve sheath tumors can originate from multiple cells such as Schwann cells, perineural cells, or fibroblasts.
Hence the tumor appearance varies greatly from case to case. This is why the diagnosis and classification of malignant peripheral nerve sheath tumor is difficult. Malignant peripheral nerve sheath tumor is a rare type of sarcoma and comprises approximately 5-10% of all soft tissue sarcomas. MPNSTs are quite rare, occurring in 0.001% of the general population. They occur either spontaneously or in association with neurofibromatosis-1 (NF1). Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1.
The worldwide incidence rate of malignant peripheral nerve sheath tumor is estimated to be 1.46 per 1,000,000 individuals. Signs and symptoms of malignant peripheral nerve sheath tumor include pain in affected area, weakness, a growing lump of tissue under the skin.
Furthermore, Meridian Market Consultants (MMC) Study identifies that the estimated lifetime risk of developing malignant peripheral nerve sheath tumor in patients with NF1 is as high as 13%. The treatment options for malignant peripheral nerve sheath tumors as similar to treatment options for other malignant tumors. Surgery is recommended for the removal of the tumor along with surrounding tissue, which may be vital for patient survival. The goal of surgical removal is to achieve complete surgical excision of the tumor with wide margins.
Radiation therapy is recommended in pre-operative, intraoperative, and post-operative settings for malignant peripheral nerve sheath tumors. Radiation therapy offers a reduction in the local recurrence of a disease. Preoperative external beam radiation therapy is administered before surgical resection. Chemotherapy is recommended for a systemic disease that is either too small to detect or too diffuse and renders local treatment techniques ineffective. Chemotherapy can be administered in the pre-operative and post-operative settings. Commonly prescribed chemotherapy drugs include doxorubicin, dactinomycin, cyclophosphamide, and vincristine.
MMC Study identifies some of the key participating players in the malignant peripheral nerve sheath tumor treatment market globally are Pfizer Inc., Janssen Pharmaceuticals (Johnson & Johnson), Baxter Healthcare, Alza Pharmaceutical Limited, Sandoz (Novartis AG), Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Recordati Rare Diseases, Inc., Eli Lilly & Co. Ltd., etc. among others.
About Meridian Market Consultants (MMC):
Meridian Market Consultants (MMC) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.
